Timothy P. Cripe, MD, PhD
Title
Director, Translational Research Trials Office; Director, Comprehensive musculoskeletal tumor clinic
Appointment
Associate Professor of Pediatrics
Email
timothy.cripe@cchmc.org
Phone
513-636-7241
Fax
513-636-3549
Bio
Timothy P. Cripe, MD, PhD, graduated Magna Cum Laude from Princeton University with a degree in Biochemistry. He completed his MD, PhD in genetics, and pediatric residency training at the University of Iowa.
Dr. Cripe was a clinical fellow in pediatric hematology/oncology at the Children's Hospital and the Dana-Farber Cancer Institute in Boston, affiliate institutions of Harvard medical School, and a research fellow at the Children's Hospital and University of Colorado Health Sciences Center in Denver. Following his subspecialty training, Dr. Cripe was an Assistant Professor of Pediatrics at the University of Wisconsin Children's Hospital and Comprehensive Cancer Center in Madison and was the Medical Director of the UW/ American Red Cross Hemophilia Treatment Center.
Dr. Cripe and his wife, a pediatric cardiologist, have three children.
Credentials
AB: Princeton University, Princeton, N.J., 1982.
MD, PhD: University of Iowa, Iowa City, Iowa, 1989.
Residency: Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, Iowa,1989-1992.
Fellowship: Dana-Farber Cancer Institute/ Children's Hospital, Boston, Mass., 1992-1993; University of Colorado Health Sciences Center/Children's Hospital, Denver, Colo., 1993-1995.
Certification: Diplomate, American Board of Pediatrics, 1993; Pediatric Hematology/ Oncology, 1996.
Awards and Honors
- Awarded, Best Doctors in America, 2008
Research
Transcriptional regulation; genetic perturbations in cancer; gene therapy of cancer; gene transfer; transcriptional targeting; antiangiogenesis; viral oncolysis; viral oncogenesis
Our primary mission and interest is the development of new therapies for cancer based on a platform of oncolytic viruses.
Research Grants and Contracts
U54 RR019498 (Trapnell) 09/30/03 – 07/31/08 NIH/NCRR
Rare Lung Disease Clinical Research Network
K30 HL078581 (Tsevat) 08/01/05-07/31/10 NIH/University of Cincinnati
Publications, Most Recent
Connect to Timothy Cripe's publications on PubMed
Applebaum H, Kieran MW, Cripe TP, Coffin CM, Collins MH, Kaipainen A, Laforme A, Shamberger RC. The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study.J Pediatr Surg. 2005 Jun;40(6):999-1003; discussion 1003.
Cripe TP, Thomson B, Boat TF, Williams DA. Promoting translational research in academic health centers: navigating the "roadmap".Acad Med. 2005 Nov;80(11):1012-8.
Parikh N, Currier MA, Adams LC, Mahller, YY, DiPasquale B, Collins MH, Cripe TP. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.Pediatr Blood Cancer. 2005 May;44(5):469-78.
Currier M, Mahller L, Adams L, Cripe T. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses.Cancer Gene Ther. 2005 Apr;12(4):407-16.
Parikh N, Hoyer J, Cripe T. A young girl with hemolytic anemia and elevated hemoglobin F.Pediatr Blood Cancer. 2005 Mar;44(3):264-6.
Halsted MJ, Perry LA, Cripe TP, Collins MH, Jakobovits R, Benton C, Halsted DG. Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences.AJR Am J Roentgenol. 2004 Feb;182(2):307-9. Review.
Dickens DS and Cripe TP. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.J Pediatr Hematol Oncol. 2003 Sep;25(9):709-14.
Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.J Pediatr Hematol Oncol. 2003 Apr;25(4):282-5.
Editing:
1999-present: Managing Editor for Pediatric Oncology Section, eMedicine Journal.
Professional Organization Memberships
- 2004-present: Member, Soft Tissue Sarcoma Committee, Children's Oncology Group
- 2000 - present: Member, Children's Oncology Group
- 2000 - present: Member, European Society of Gene Therapy
- 2000 - present: Member, American Society of Gene Therapy
- 1999 - present: Member, American Association for Cancer Research
- 1995 - present: Member, Association for the Advancement of Science
- 1995 - present: Member, American Society of Pediatric Hematology / Oncology
- 1994 - present: Member, American Society of Hematology
Special Interests
Gene and viral therapy for cancer; bone and soft tissue sarcomas
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
